Literature DB >> 29963993

Conjugated Bile Acids Promote Invasive Growth of Esophageal Adenocarcinoma Cells and Cancer Stem Cell Expansion via Sphingosine 1-Phosphate Receptor 2-Mediated Yes-Associated Protein Activation.

Runping Liu1, Xiaojiaoyang Li1, Phillip B Hylemon1, Huiping Zhou2.   

Abstract

Esophageal adenocarcinoma (EAC) is the sixth leading cause of cancer deaths worldwide and has been dramatically increasing in incidence over the past decade. Gastroesophageal reflux and Barrett esophagus are well-established risk factors for disease progression. Conjugated bile acids (CBAs), including taurocholate (TCA), represent the major bile acids in the gastroesophageal refluxate of advanced Barrett esophagus and EAC patients. Our previous studies suggested that CBA-induced activation of sphingosine 1-phosphate receptor 2 (S1PR2) plays a critical role in promoting cholangiocarcinoma cell invasive growth. However, the role of CBAs in EAC development and underlying mechanisms remains elusive. In the current study, we identified that the expression level of S1PR2 is correlated to invasiveness of EAC cells. TCA significantly promoted cell proliferation, migration, invasion, transformation, and cancer stem cell expansion in highly invasive EAC cells (OE-33 cells), but had less effect on the lower invasive EAC cells (OE-19 cells). Pharmacologic inhibition of S1PR2 with specific antagonist JTE-013 or knockdown of S1PR2 expression significantly reduced TCA-induced invasive growth of OE-33 cells, whereas overexpression of S1PR2 sensitized OE-19 cells to TCA-induced invasive growth. Furthermore, TCA-induced activation of S1PR2 was closely associated with YAP and β-catenin signaling pathways. In conclusion, CBA-induced activation of the S1PR2 signaling pathway is critically involved in invasive growth of EAC cells and represents a novel therapeutic target for EAC.
Copyright © 2018 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29963993      PMCID: PMC6105923          DOI: 10.1016/j.ajpath.2018.05.015

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   5.770


  66 in total

Review 1.  TGF-beta and epithelial-to-mesenchymal transitions.

Authors:  Jiri Zavadil; Erwin P Böttinger
Journal:  Oncogene       Date:  2005-08-29       Impact factor: 9.867

Review 2.  Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond.

Authors:  Gregory T Kunkel; Michael Maceyka; Sheldon Milstien; Sarah Spiegel
Journal:  Nat Rev Drug Discov       Date:  2013-08-19       Impact factor: 84.694

3.  Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.

Authors:  Anna Mokrowiecka; Lothar Veits; Christina Falkeis; Jacek Musial; Radzislaw Kordek; Mariusz Lochowski; Jozef Kozak; Agnieszka Wierzchniewska-Lawska; Michael Vieth; Ewa Malecka-Panas
Journal:  Pathol Res Pract       Date:  2016-12-30       Impact factor: 3.250

Review 4.  Regulatory networks defining EMT during cancer initiation and progression.

Authors:  Bram De Craene; Geert Berx
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

5.  Epithelial mesenchymal transition and cancer stem cells in esophageal adenocarcinoma originating from Barrett's esophagus.

Authors:  Yutaka Tomizawa; Tsung-Teh Wu; Kenneth K Wang
Journal:  Oncol Lett       Date:  2012-03-05       Impact factor: 2.967

Review 6.  Reflux injury of esophageal mucosa: experimental studies in animal models of esophagitis, Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Yan Li; Robert C G Martin
Journal:  Dis Esophagus       Date:  2007       Impact factor: 3.429

Review 7.  Sphingosine-1-phosphate receptor subtype 2 signaling in endothelial senescence-associated functional impairments and inflammation.

Authors:  Jiawei Zhao; Dante Garcia; Allison Gartung; Menq-Jer Lee
Journal:  Curr Atheroscler Rep       Date:  2015-05       Impact factor: 5.113

Review 8.  History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus.

Authors:  Stuart Jon Spechler; Rebecca C Fitzgerald; Ganapathy A Prasad; Kenneth K Wang
Journal:  Gastroenterology       Date:  2010-01-18       Impact factor: 22.682

9.  Aberrant expression of the S1P regulating enzymes, SPHK1 and SGPL1, contributes to a migratory phenotype in OSCC mediated through S1PR2.

Authors:  Sathya Narayanan Patmanathan; Steven P Johnson; Sook Ling Lai; Suthashini Panja Bernam; Victor Lopes; Wenbin Wei; Maha Hafez Ibrahim; Federico Torta; Pradeep Narayanaswamy; Markus R Wenk; Deron R Herr; Paul G Murray; Lee Fah Yap; Ian C Paterson
Journal:  Sci Rep       Date:  2016-05-10       Impact factor: 4.379

Review 10.  Expansion of Sphingosine Kinase and Sphingosine-1-Phosphate Receptor Function in Normal and Cancer Cells: From Membrane Restructuring to Mediation of Estrogen Signaling and Stem Cell Programming.

Authors:  Olga A Sukocheva
Journal:  Int J Mol Sci       Date:  2018-01-31       Impact factor: 5.923

View more
  17 in total

1.  YAP-dependent metabolic remodeling in local lymph node boosts the function of cancer cells.

Authors:  Toshihide Kashihara; Daniela Zablocki; Junichi Sadoshima
Journal:  Biotarget       Date:  2019-08-23

2.  Design, synthesis, and in vitro bioactivity evaluation of fluorine-containing analogues for sphingosine-1-phosphate 2 receptor.

Authors:  Zonghua Luo; Hui Liu; Robyn S Klein; Zhude Tu
Journal:  Bioorg Med Chem       Date:  2019-06-29       Impact factor: 3.641

3.  Synthesis and characterization of [125I]TZ6544, a promising radioligand for investigating sphingosine-1-phosphate receptor 2.

Authors:  Zonghua Luo; Qianwa Liang; Hui Liu; Joshi Sumit; Hao Jiang; Robyn S Klein; Zhude Tu
Journal:  Nucl Med Biol       Date:  2020-07-27       Impact factor: 2.408

4.  ABCA8-mediated efflux of taurocholic acid contributes to gemcitabine insensitivity in human pancreatic cancer via the S1PR2-ERK pathway.

Authors:  Chunmei Yang; Hui Yuan; Jinyang Gu; Dengfei Xu; Mingwei Wang; Jie Qiao; Xi Yang; Jian Zhang; Ming Yao; Jianren Gu; Hong Tu; Yu Gan
Journal:  Cell Death Discov       Date:  2021-01-11

5.  Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases.

Authors:  Arun J Sanyal; Lei Ling; Ulrich Beuers; Alex M DePaoli; Hsiao D Lieu; Stephen A Harrison; Gideon M Hirschfield
Journal:  JHEP Rep       Date:  2021-02-19

Review 6.  Roles of G Protein-Coupled Receptors (GPCRs) in Gastrointestinal Cancers: Focus on Sphingosine 1-Shosphate Receptors, Angiotensin II Receptors, and Estrogen-Related GPCRs.

Authors:  Zhen Zeng; Chunxiang Ma; Kexin Chen; Mingshan Jiang; Reshma Vasu; Rui Liu; Yinglan Zhao; Hu Zhang
Journal:  Cells       Date:  2021-11-03       Impact factor: 6.600

Review 7.  Models for Understanding Resistance to Chemotherapy in Liver Cancer.

Authors:  Jose J G Marin; Elisa Herraez; Elisa Lozano; Rocio I R Macias; Oscar Briz
Journal:  Cancers (Basel)       Date:  2019-10-29       Impact factor: 6.639

8.  Ursodeoxycholic acid suppresses the malignant progression of colorectal cancer through TGR5-YAP axis.

Authors:  Huan Zhang; Huanji Xu; Chenliang Zhang; Qiulin Tang; Feng Bi
Journal:  Cell Death Discov       Date:  2021-08-07

9.  High-Fructose Diet Alters Intestinal Microbial Profile and Correlates with Early Tumorigenesis in a Mouse Model of Barrett's Esophagus.

Authors:  Andrea Proaño-Vasco; Theresa Baumeister; Amira Metwaly; Sandra Reitmeier; Karin Kleigrewe; Chen Meng; Michael Gigl; Thomas Engleitner; Rupert Öllinger; Roland Rad; Katja Steiger; Akanksha Anand; Julia Strangmann; Robert Thimme; Roland M Schmid; Timothy C Wang; Michael Quante
Journal:  Microorganisms       Date:  2021-11-25

Review 10.  Sphingolipid metabolism in the development and progression of cancer: one cancer's help is another's hindrance.

Authors:  Antonia Piazzesi; Sumaiya Yasmeen Afsar; Gerhild van Echten-Deckert
Journal:  Mol Oncol       Date:  2021-07-29       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.